These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 32668113)
1. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H; N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113 [TBL] [Abstract][Full Text] [Related]
2. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472 [TBL] [Abstract][Full Text] [Related]
3. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study. Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. de Moraes-Souza R; Chahine Chater R; Pera Calvi I; Mesquita Y; Sarto R; Lapenda I; Figueiredo Pereira L; Moury L; Herranz-Pinto P Clin Drug Investig; 2024 Sep; 44(9):655-665. PubMed ID: 39172296 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Stein Gold L; Adam DN; Albrecht L; Alonso-Llamazares J; Ferris LK; Gooderham MJ; Hong HC; Kempers SE; Kircik LH; Lebwohl M; Loo WJ; Nahm WK; Papp KA; Stewart D; Toth DP; Zirwas M; Krupa D; Snyder S; Burnett P; Higham R; Berk DR J Am Acad Dermatol; 2024 Aug; 91(2):273-280. PubMed ID: 38556093 [TBL] [Abstract][Full Text] [Related]
6. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Snape SD; Wigger-Alberti W; Goehring UM Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440 [TBL] [Abstract][Full Text] [Related]
7. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis. Smith B; Collier MR; Wu JJ JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326 [No Abstract] [Full Text] [Related]
9. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial. Stein Gold L; Alonso-Llamazares J; Draelos ZD; Gooderham MJ; Kempers SE; Kircik LH; Lebwohl MG; Papp KA; Pariser DM; Toth DP; Yosipovitch G; Higham RC; Feng A; Berk DR Am J Clin Dermatol; 2023 Mar; 24(2):305-313. PubMed ID: 36370336 [TBL] [Abstract][Full Text] [Related]
10. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448 [TBL] [Abstract][Full Text] [Related]
11. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681 [TBL] [Abstract][Full Text] [Related]
12. Roflumilast cream (Zoryve) for atopic dermatitis. Med Lett Drugs Ther; 2024 Sep; 66(1711):150-151. PubMed ID: 39250342 [No Abstract] [Full Text] [Related]
13. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO). Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial. Zirwas MJ; Draelos ZD; DuBois J; Kircik LH; Moore AY; Stein Gold L; Alonso-Llamazares J; Bukhalo M; Bruce S; Eads K; Green LJ; Guenthner ST; Ferris LK; Forman SB; Kempers SE; Lain E; Lynde CW; Pariser DM; Toth DP; Yamauchi PS; Higham RC; Krupa D; Burnett P; Berk DR JAMA Dermatol; 2023 Jun; 159(6):613-620. PubMed ID: 37133856 [TBL] [Abstract][Full Text] [Related]
15. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis. Pixley JN; Schaetzle T; Feldman SR Ann Pharmacother; 2023 Aug; 57(8):966-969. PubMed ID: 36420929 [TBL] [Abstract][Full Text] [Related]
16. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities. Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials. Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780 [TBL] [Abstract][Full Text] [Related]
18. Polymorphous Light Eruptions Treated With Roflumilast 0.3% Cream: A Case Report. Garg KS; Kircik L; Tjahjono L J Drugs Dermatol; 2024 Aug; 23(8):686-687. PubMed ID: 39093641 [No Abstract] [Full Text] [Related]